Clinical trials: Dry Eye
Dry Eye
The Effect of Systane Ultra Lubricant Eye Drops (FID 112903) on Visual Performance
To evaluate the effect of 2 different lubricant eye drops on visual function of patients with dry eye
- Trial name
- NCT00673764
- Testing
- Systane Ultra Lubricant Eye Drops, Optive Lubricant Eye Drops
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Alcon Research
Dry Eye Disease
A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease
The objective of the study is to assess the safety, efficacy, optimum dosage, and dosing regimen of K-161 in adult subjects with moderate to severe dry eye disease.
- Trial name
- NCT04084483
- Testing
- K-161
- Where
- 4 sites in United States
- Volunteers
- 238 people
- Sponsor
- Kowa Research Institute, Inc.
Keratoconjunctivitis Sicca
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS).
- Trial name
- NCT00349466
- Testing
- CF101
- Where
- 3 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Can-Fite BioPharma
Sjögren Syndrome
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
- Trial name
- TWINSS (NCT03905525)
- Testing
- CFZ533
- Where
- 71 sites in United States, Argentina and 21 more
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Syndrome
Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome
The purpose of this study is to evaluate the efficacy and safety of PRO-148 ophthalmic solution compared with SYSTANE ® ophthalmic solution for the treatment of signs and symptoms of mild-to-moderate dry eye syndrome.
- Trial name
- PRO-148 (NCT01541891)
- Testing
- PRO-148 Ophthalmic Solution, Active Comparator: SYSTANE ® Ophthalmic Solution
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye
The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye
The purpose of this study is to determine whether Restasis is an effective treatment for preventing the occurrence and progression of dry eye syndrome in patients who have recently received a bone marrow transplant and are at…
- Trial name
- NCT00553735
- Testing
- Cyclosporine A 0.05%, Arificial Tear
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Dry Eye Disease
IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
Double-masked, dose-response, trial of IVW-1001 in subjects with dry eye disease.
- Trial name
- NCT06400459
- Testing
- IVW-1001 Ophthalmic Eyelid Wipe 0.1%, IVW-1001 Ophthalmic Eyelid Wipe 0.2%
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- IVIEW Therapeutics Inc.
Contact Lens Discomfort, Dry Eye
Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort
Clinicians commonly use artificial tears off label for treating contact lens (CL) discomfort and the dry eye associated with CLs because new artificial tear formulations have the potential to outperform the available CL rewetting…
- Trial name
- NCT03682809
- Testing
- Systane Complete
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of Alabama at Birmingham
Dry Eye Syndromes
Efficacy of T2259 in DED
The purpose of this study is to compare the performance and safety of T2259 versus Vismed Multi in dry eye patients with superficial keratitis.
- Trial name
- NCT03874429
- Testing
- T2259, Vismed multi
- Where
- France
- Volunteers
- 101 people
- Sponsor
- Laboratoires Thea
Dry Eye Disease
Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo in simulating Goblet Cell and Meibomian Gland function in adult subjects with DED.
- Trial name
- NCT03688802
- Testing
- OC-01 (varenicline) nasal spray
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Oyster Point Pharma, Inc.
Dry Eye Syndromes, Dry Eye
Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction
A Randomized, Masked (Evaluator), Controlled, Prospective Pilot Study of the Effectiveness and Safety of the Tixel®, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction.
- Conditions
- Dry Eye Syndromes, Dry Eye, Meibomian Gland Dysfunction
- Trial name
- NCT04889950
- Testing
- Tixel C, LipiFlow
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Novoxel Ltd.
Sjögren's Syndrome
A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).
- Trial name
- SS (NCT04129164)
- Testing
- VIB4920
- Where
- 62 sites in United States, Argentina and 10 more
- Volunteers
- 183 people
- Sponsor
- Amgen
Dry Eye
The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients
This study assessed the effects of a single intravenous dose of secukinumab (AIN457) 10 mg/kg or canakinumab (ACZ885) 10 mg/kg on the signs and symptoms of dry eye.
- Trial name
- NCT01250171
- Testing
- Secukinumab 10 mg/kg, Canakinumab 10 mg/kg
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye
Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
Dose response related to efficacy and safety of DE-089 ophthalmic solution are examined in patients with dry eye, using a multicenter, randomized, double-blind, parallel group comparison study, and the optimal concentration is…
- Trial name
- NCT01189032
- Testing
- DE-089 ophthalmic solution
- Where
- Japan
- Volunteers
- 320 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Dry Eye
A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye
The purpose of this study is to compare the efficacy and safety of HBM9036 Ophthalmic Solution versus placebo in the treatment of dry eye
- Trial name
- NCT04092907
- Testing
- HBM9036 0.25% Ophthalmic Solution
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Dry Eye Syndromes
A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants
This study will evaluate the safety, tolerability and efficacy of IC265 compared to vehicle in participants with signs and symptoms dry eye disease.
- Trial name
- NCT05992922
- Testing
- IC265 Ophthalmic Solution 1%
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Iacta Pharmaceuticals
Keratoconjunctivitis Sicca
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02121301
- Testing
- Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Mitotech, SA
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- Kauai (NCT02188160)
- Testing
- KPI-121
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye Syndromes
Impairment of Reading Ability in Dry Eye Patients
To assess the reading function impairment in patients with dry eye and to assess the effects of reading on the ocular surface.
- Trial name
- NCT01826812
- Testing
- 30 minutes sustained reading, Dry eye exam
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Dry Eye Disease
A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
Primary objective To evaluate the efficacy of 5 μg/mL and 10 μg/mL concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least 1 of the concentrations over…
- Trial name
- REDUCO (NCT06244316)
- Testing
- rhNGF 5 μg/mL, rhNGF 10 μg/mL
- Where
- 14 sites in United States, Italy
- Volunteers
- 317 people
- Sponsor
- Dompé Farmaceutici S.p.A